ABL1 and myeloproliferative disorder: Additionally, these previous studies indicate that the V617F mutation is the major molecular maker for pathogenesis in BCR/ABL-negative MPN patients, therefore, the V617F mutation may act as an important molecular genetic and diagnostic marker for BCR/ABL-negative MPN (5,6,9,10).